Actuate Therapeutics Insider Trades
NASDAQ: ACTUHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 1 · $50.00K
- Sales
- 1 · $1.62M
- Shares bought / sold
- 140.84K / 280.00K
- Net activity
- Net selling $1.6 million
Actuate Therapeutics insider activity
Over the last 12 months, Actuate Therapeutics insiders reported 6 transactions on SEC Form 4: 1 open-market purchase and 1 sale. Insiders bought $50,000 and sold $1.6 million worth of stock, for net insider selling of $1.6 million. The largest seller was THOMSON TODD S & Kairos Venture Partners II, L.P., with $1.6 million in reported sales.
The most recent filing shows SCHMITT DANIEL M (President, CEO and Director) buying 140,844 shares at $0.355 on Oct 28, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put ACTU's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
ACTU insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Oct 28, 2026 | SCHMITT DANIEL MPresident, CEO and Director | Buy | 140,844 | $50.00K | Form 4 |
| Aug 14, 2026 | SCHMITT DANIEL MPresident, CEO and Director | Tax withholding | 120,521 | $121.73K | Form 4 |
| Aug 14, 2026 | SCHMITT DANIEL MPresident, CEO and Director | Option exercise | 272,056 | — | Form 4 |
| Feb 13, 2026 | SCHMITT DANIEL MPresident, CEO and Director | Tax withholding | 121,874 | $527.71K | Form 4 |
| Feb 13, 2026 | SCHMITT DANIEL MPresident, CEO and Director | Option exercise | 272,055 | — | Form 4 |
| Jan 5, 2026 | THOMSON TODD S & Kairos Venture Partners II, L.P.Director | Sale | 280,000 | $1.62M | Form 4 |
| Jun 27, 2025 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LPDirector | Buy | 71,428 | $500.00K | Form 4 |
| Jun 27, 2025 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & Bios 2024 Co-Invest, LP & BP Directors, LPDirector | Buy | 71,428 | $500.00K | Form 4 |
| Jun 27, 2025 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Buy | 71,428 | $500.00K | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 176,499 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 54,032 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 153,702 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 61,857 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 462,073 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 141,457 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 307,538 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 525,797 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Buy | 125,000 | $1.00M | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Buy | 375,000 | $3.00M | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Conversion | 884,427 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Sale | 2,324 | $20.92K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Option exercise | 3,528 | $18.59K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Sale | 17,361 | $156.25K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Option exercise | 26,355 | $138.89K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Sale | 5,314 | $47.83K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Option exercise | 8,068 | $42.52K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 573,394 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 78,267 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 484,638 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 74,202 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 2,094,650 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 326,547 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 2,022,029 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 309,589 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 44,559 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 332,867 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 101,900 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 147,047 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 23,628 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 176,499 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 54,032 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 153,702 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 61,857 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 462,073 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 141,457 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 307,538 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 525,797 | — | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Buy | 125,000 | $1.00M | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Buy | 375,000 | $3.00M | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Conversion | 884,427 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Sale | 2,324 | $20.92K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Option exercise | 3,528 | $18.59K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Sale | 17,361 | $156.25K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Option exercise | 26,355 | $138.89K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Sale | 5,314 | $47.83K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Option exercise | 8,068 | $42.52K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 573,394 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 78,267 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 484,638 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 74,202 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 2,094,650 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 326,547 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 2,022,029 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 309,589 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 44,559 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 332,867 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 101,900 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 147,047 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 23,628 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 176,499 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 54,032 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 153,702 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 61,857 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 462,073 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 141,457 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 307,538 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 525,797 | — | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Buy | 125,000 | $1.00M | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Buy | 375,000 | $3.00M | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Conversion | 884,427 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Sale | 18,750 | $150.00K | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Option exercise | 28,464 | $150.01K | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 49,984 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 24,138 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 132,908 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 230,597 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 138,889 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 146,870 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 69,445 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 726,163 | — | Form 4 |
| Aug 14, 2024 | THOMSON TODD S & Kairos SPV Fund LLC & Kairos Venture Opportunities I, L.P. & Kairos Venture Partners II, L.P. & Kairos-Actuate SPV, L.P.Director | Conversion | 1,058,318 | — | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Sale | 2,324 | $18.59K | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Sale | 17,361 | $138.89K | Form 4 |
| Aug 14, 2024 | Kreis Leslie W. & Cavu Advisors, LLC & Cavu Management, LP & BIOS Fund I, LP & BIOS Fund I QP, LP & Bios Equity Partners, LP & BIOS Fund II, LP & BIOS Fund II NT, LP & BIOS Fund II QP, LP & Bios Equity Partners II, LP10% Owner | Sale | 5,314 | $42.51K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Sale | 2,324 | $18.59K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Sale | 17,361 | $138.89K | Form 4 |
| Aug 14, 2024 | Fletcher Aaron G.L. & BIOS Capital Management, LP & BIOS Advisors GP, LLC & BIOS Fund III, LP & BIOS Fund III QP, LP & BIOS Fund III NT, LP & BIOS Actuate Co-Invest I, LP & BIOS Actuate Co-Invest II, LP & Bios Actuate Co-Invest III, LP & BIOS Equity Partners III, LPDirector | Sale | 5,314 | $42.51K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Sale | 2,324 | $18.59K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Sale | 17,361 | $138.89K | Form 4 |
| Aug 14, 2024 | Bios Equity COF, LP & Bios Clinical Opportunity Fund, LP & BP Directors, LPDirector | Sale | 5,314 | $42.51K | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4